By-Madol SR 150 mg prolonged-release capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

by-madol sr 150 mg prolonged-release capsules, hard

ethypharm - tramadol hydrochloride - prolonged-release capsule, hard - 150 milligram(s) - other opioids; tramadol

By-Madol SR 200 mg prolonged-release Ireland - English - HPRA (Health Products Regulatory Authority)

by-madol sr 200 mg prolonged-release

ethypharm - tramadol hydrochloride - prolonged-release capsule, hard - 200 milligram(s) - other opioids; tramadol

By-Madol SR 50 mg prolonged-release capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

by-madol sr 50 mg prolonged-release capsules, hard

ethypharm - tramadol hydrochloride - prolonged-release capsule, hard - 50 milligram(s) - other opioids; tramadol

By-Madol SR 100 mg prolonged-release capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

by-madol sr 100 mg prolonged-release capsules, hard

ethypharm - tramadol hydrochloride - prolonged-release capsule, hard - 100 milligram(s) - other opioids; tramadol

MAXITROL OPHTHALMIC SUSPENSION Israel - English - Ministry of Health

maxitrol ophthalmic suspension

novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophthalmic suspension - dexamethasone 1.0 mg/ml; neomycin as sulfate 3,500 iu/ml; polymyxin b sulfate 6000 iu/ml - polymyxin b - polymyxin b - maxitrol is indicated in ocular inflammation when concurrent use of antimicrobial in judged necessary.

MAXITROL- neomycin sulfate, polymyxin b sulfate and dexamethasone suspension United States - English - NLM (National Library of Medicine)

maxitrol- neomycin sulfate, polymyxin b sulfate and dexamethasone suspension

harrow eye, llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae , klebsiella /enterobacter species, neisseria species, and pseudomonas aeruginosa . this product does not provide adequate coverage against: serratia marcescens and s treptococci , including streptococcus pneumoniae . maxitrol ® (neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. maxitrol is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.